Cell Cycle / Checkpoint Control
CDK9 (C12F7) Rabbit mAb |
イイネ!(0) |
|
| CSTコード | 包装 | 希望納入価格 (円) |
||
|---|---|---|---|---|
| #2316S | 100 μL | 46,000 | ログインすると国内在庫状況がご確認いただけます。
| |
| #2316P | 40 μL for Custom Sampler Kit | ![]() Custom Antibody Sampler Kitの構成品を選択できます。 5本以上を選択し、ページ右上のCartから製品確定書を発行してください。 尚、構成品の単品販売は致しておりません。 |
シグナル伝達研究応援キャンペーン プレゼント *Pサイズのみ
下記ステップについては、データシートの右側もあわせてご参照ください。
IHC-F: 固定
IHC-P: 抗体希釈液 / 抗原賦活化
| 用途 (希釈倍率) | |
|---|---|
| ウェスタンブロッティング (1:1,000)、免疫沈降 (1:100)、免疫組織染色 (パラフィン) (1:200)、免疫組織染色 (凍結) (1:200)、免疫蛍光細胞染色 (IF-IC) (1:100)、フローサイトメトリー (1:200) |
| 種交差性 | |
|---|---|
| ヒト、マウス、ラット、サル、ハムスター、ウシ、イヌ |
| 特異性・感度 | |
|---|---|
| 内在性レベルのCDK9 タンパク質の42 kDa と55 kDa の両アイソフォームを検出します。 |
| 検出タンパク質の分子量 | |
|---|---|
| 42 kDa、55 kDa |
| 使用抗原 | |
|---|---|
| ヒトのCDK9 タンパク質のC末端近傍領域 (合成ペプチド) |
| 抗体の由来 | |
|---|---|
| ウサギ |
| 貯法 | |
|---|---|
| -20℃ |
| 社内データ |
|---|
Western Blotting

Western blot analysis of extracts from various cell types using CDK9 (C12F7) Rabbit mAb.
IP

Immunoprecipitation of CDK9 from HeLa cells using CDK9 (C12F7) Rabbit mAb. Western blot detection was performed using the same antibody. Lane 1 is 5% input.
IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded human breast carcinoma using CDK9 (C12F7) Rabbit mAb in the presence of control peptide (left) or antigen specific peptide (right).
IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded K7M2 mouse syngeneic tumor using CDK9 (C12F7) Rabbit mAb.
IHC-F (frozen)

Immunohistochemical analysis of frozen SKOV-3 xenograft using CDK9 (C12F7) Rabbit mAb.
Flow Cytometry

Flow cytometric analysis of Jurkat cells using CDK9 (C12F7) Rabbit mAb (blue) compared to a nonspecific negative control antibody (red).
| バックグラウンド |
|---|
P-TEFb is a general transcription factor that regulates transcription elongation through phosphorylation of the C-terminal tail domain (CTD) of RNA polymerase II (RNAP II). The P-TEFb complex composed of a catalytic subunit, CDK9, and its regulatory cyclin partner, which can be cyclin T1, T2a, T2b or K (reviewed in 1,2). P-TEFb is recruited by the HIV Tat protein to allow transcriptional elongation, and subsequent replication of the viral genome. Inhibition of P-TEFb function therefore has potential for HIV therapy.CDK9 exists as two isoforms, an abundant 42 kDa isoform, and a less abundant 55 kDa isoform, which contains an amino-terminal extension (3). The two forms likely have distinct purposes based on differential expression during lymphocyte activation (4,5) and on their localization within the nucleus (5).Cyclin dependent kinases (CDKs) are activated in part by cyclin binding and by phosphorylation of a conserved threonine in the T-loop domain. Phosphorylation of CDK9 at the T-loop Thr186 by an unidentified nuclear kinase may be important in P-TEFb activation (6) and regulation of HIV transcription (7). Acetylation of CDK9 at Lys44 affects its ability to phosphorylate the RNAPII CTD (8).
- Rice, A.P. and Herrmann, C.H. (2003) Curr HIV Res 1, 395-404.
- De Falco, G. and Giordano, A. Cancer Biol Ther 1, 342-7.
- Shore, S.M. et al. (2003) Gene 307, 175-82.
- Shore, S.M. et al. (2005) Gene 350, 51-8.
- Liu, H. and Herrmann, C.H. (2005) J Cell Physiol 203, 251-60.
- Chen, R. et al. (2004) J Biol Chem 279, 4153-60.
- Ammosova, T. et al. (2005) Retrovirology 2, 47.
- Fu, J. et al. (2007) Mol Cell Biol 27, 4641-51.
| 使用例 | |
|---|---|
| 製品をご使用いただいて研究を発表されましたら、ぜひお知らせください。 |
本製品は試験研究用です。


